Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children

키워드

참고문헌 (97)

1. Fisher RS, "ILAE official report : a practical clinical definition of epilepsy", Epilepsia, 55, pp.475~482 (2014)
2. Fiest KM, "Prevalence and incidence of epilepsy : A systematic review and meta-analysis of international studies", Neurology, 88, pp.296~303 (2017)
3. Aaberg KM, "Incidence and prevalence of childhood epilepsy : a nationwide cohort study", Pediatrics, 139, pp.e20163908~ (2017)
4. Kwan P, "Early identification of refractory epilepsy", N Engl J Med, 342, pp.314~319 (2000)
5. Beghi E, "Epidemiologic aspects : lost in transition", Epilepsia, 55(Suppl 3), pp.3~7 (2014)
6. Ohtahara S, "Ohtahara syndrome : with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy", Epilepsy Res, 70(Suppl 1), pp.S58~S67 (2006)
7. Yamatogi Y, "Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases", Brain Dev, 24, pp.13~23 (2002)
8. Auvin S, "Current understanding and neurobiology of epileptic encephalopathies", Neurobiol Dis, 92, pp.72~89 (2016)
9. McTague A, "The genetic landscape of the epileptic encephalopathies of infancy and childhood", Lancet Neurol, 15, pp.304~316 (2016)
10. Guerrini R, "Dravet syndrome : the main issues", Eur J Paediatr Neurol, 16(Suppl 1), pp.S1~S4 (2012)
11. Dravet C, "The core Dravet syndrome phenotype", Epilepsia, 52(Suppl 2), pp.3~9 (2011)
12. Claes L, "De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy", Am J Hum Genet, 68, pp.1327~1332 (2001)
13. Wallace RH, "Sodium channel α1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms", Neurology, 61, pp.765~769 (2003)
14. Carvill GL, "GABRA1 and STXBP1 : novel genetic causes of Dravet syndrome", Neurology, 82, pp.1245~1253 (2014)
15. Marini C, "The genetics of Dravet syndrome", Epilepsia, 52(Suppl 2), pp.24~29 (2011)
16. Arzimanoglou A, "Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology", Lancet Neurol, 8, pp.82~93 (2009)
17. Camfield PR, "Definition and natural history of Lennox-Gastaut syndrome", Epilepsia, 52(Suppl 5), pp.3~9 (2011)
18. Engel J Jr, "Excitation and inhibition in epilepsy", Can J Neurol Sci, 23, pp.167~174 (1996)
19. Smith EH, "Toward a mechanistic understanding of epileptic networks", Curr Neurol Neurosci Rep, 16, pp.97~ (2016)
20. Naylor DE, "Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus", Neurobiol Dis, 54, pp.225~238 (2013)
21. Prince DA, "Control mechanisms in cortical epileptogenic foci. “Surround” inhibition", Arch Neurol, 16, pp.194~202 (1967)
22. de Lera Ruiz M, "Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications", J Med Chem, 58, pp.7093~7118 (2015)
23. Trimmer JS, "Localization of voltage-gated ion channels in mammalian brain", Annu Rev Physiol, 66, pp.477~519 (2004)
24. Yu FH, "Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy", Nat Neurosci, 9, pp.1142~1149 (2006)
25. Cheah CS, "Specific deletion of Nav1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome", Proc Natl Acad Sci U S A, 109, pp.14646~14651 (2012)
26. Sun Y, "A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet Syndrome patients", Elife, 5, pp.e13073~ (2016)
27. Liu Y, "Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism", Ann Neurol, 74, pp.128~139 (2013)
28. Patino GA, "A functional null mutation of SCN1B in a patient with Dravet syndrome", J Neurosci, 29, pp.10764~10778 (2009)
29. Kruger LC, "β1-C121W is down but not out : epilepsy-associated Scn1b-C121W results in a deleterious gain-of-function", J Neurosci, 36, pp.6213~6224 (2016)
30. Reid CA, "Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome", Brain, 137, pp.1701~1715 (2014)
31. Allen NM, "Genetic potassium channel-associated epilepsies : Clinical review of the Kv family", Eur J Paediatr Neurol, 24, pp.105~116 (2020)
32. Thiffault I, "A novel epileptic encephalopathy mutation in KCNB1 disrupts Kv2.1 ion selectivity, expression, and localization", J Gen Physiol, 146, pp.399~410 (2015)
33. Weckhuysen S, "KCNQ2 encephalopathy : emerging phenotype of a neonatal epileptic encephalopathy", Ann Neurol, 71, pp.15~25 (2012)
34. Du J, "The K+ channel, Kv2.1, is apposed to astrocytic processes and is associated with inhibitory postsynaptic membranes in hippocampal and cortical principal neurons and inhibitory interneurons", Neuroscience, 84, pp.37~48 (1998)
35. Speca DJ, "Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and behavioral hyperexcitability", Genes Brain Behav, 13, pp.394~408 (2014)
36. Misonou H, "Kv2.1: a voltage-gated K+channel critical to dynamic control of neuronal excitability", Neurotoxicology, 26, pp.743~752 (2005)
37. Schwarz JR, "KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier", J Physiol, 573, pp.17~34 (2006)
38. Brown DA, "Neural KCNQ(Kv7)channels", Br J Pharmacol, 156, pp.1185~1195 (2009)
39. Schroeder BC, "Moderate loss of function of cyclic-AMP-modulated KCNQ2", KCNQ3 K+ channels causes epilepsy, 1998, pp.396, 687~690
40. Otto JF, "A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons", J Neurosci, 26, pp.2053~2059 (2006)
41. Catterall WA, "Structure and regulation of voltage-gated Ca2+ channels", Annu Rev Cell Dev Biol, 16, pp.521~555 (2000)
42. Catterall WA, "Voltage-gated calcium channels", Cold Spring Harb Perspect Biol, 3, pp.a003947~ (2011)
43. Rossignol E, "Cav2.1 ablation in cortical interneurons selectively impairs fast-spiking basket cells and causes generalized seizures", Ann Neurol, 74, pp.209~222 (2013)
44. Heine M, "Surface traffic in synaptic membranes", Adv Exp Med Biol, 970, pp.197~219 (2012)
45. van Vliet EA, "Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy", Epilepsia, 50, pp.422~433 (2009)
46. Raimondi A, "Overlapping role of dynamin isoforms in synaptic vesicle endocytosis", Neuron, 70, pp.1100~1114 (2011)
47. Yamashita S, "Mislocalization of syntaxin-1 and impaired neurite growth observed in a human iPSC model for STXBP1-related epileptic encephalopathy", Epilepsia, 57, pp.e81~6 (2016)
48. Verhage M, "Synaptic assembly of the brain in the absence of neurotransmitter secretion", Science, 287, pp.864~869 (2000)
49. Saitsu H, "Jasper’s basic mechanisms of the epilepsies" (2012), National Center for Biotechnology Information
50. Toonen RF, "Munc18-1 in secretion : lonely Munc joins SNARE team and takes control", Trends Neurosci, 30, pp.564~572 (2007)
51. Toonen RF, "Munc18-1 expression levels control synapse recovery by regulating readily releasable pool size", Proc Natl Acad Sci U S A, 103, pp.18332~18337 (2006)
52. Reiner A, "Glutamatergic signaling in the central nervous system : ionotropic and metabotropic receptors in concert", Neuron, 98, pp.1080~1098 (2018)
53. Farrant M, "Variations on an inhibitory theme : phasic and tonic activation of GABAA receptors", Nat Rev Neurosci, 6, pp.215~229 (2005)
54. Kodera H, "De novo GABRA1 mutations in Ohtahara and West syndromes", Epilepsia, 57, pp.566~573 (2016)
55. Janve VS, "Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function", Ann Neurol, 79, pp.806~825 (2016)
56. Lachance-Touchette P, "Novel α1 and γ2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy", Eur J Neurosci, 34, pp.237~249 (2011)
57. Reid CA, "Multiple molecular mechanisms for a single GABAA mutation in epilepsy", Neurology, 80, pp.1003~1008 (2013)
58. Warner TA, "Differential molecular and behavioural alterations in mouse models of GABRG2 haploinsufficiency versus dominant negative mutations associated with human epilepsy", Hum Mol Genet, 25, pp.3192~3207 (2016)
59. Qu S, "GABAA receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice", Brain Commun (2020)
60. Trevathan E, "Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome", N Engl J Med, 339, pp.851~852 (1998)
61. Eriksson AS, "The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study", Epilepsia, 39, pp.495~501 (1998)
62. Stefani A, "Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies", Exp Neurol, 147, pp.115~122 (1997)
63. Glauser T, "Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome", Neurology, 70, pp.1950~1958 (2008)
64. Bialer M, "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)", Epilepsy Res, 43, pp.11~58 (2001)
65. Gilchrist J, "Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents", ACS Chem Biol, 9, pp.1204~1212 (2014)
66. Perucca E, "Rufinamide : clinical pharmacokinetics and concentration-response relationships in patients with epilepsy", Epilepsia, 49, pp.1123~1141 (2008)
67. Kim HJ, "Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome", Pediatr Neurol, 51, pp.527~531 (2014)
68. Dressler A, "Efficacy and tolerability of the ketogenic diet in Dravet syndrome-Comparison with various standard antiepileptic drug regimen", Epilepsy Res, 109, pp.81~89 (2015)
69. Chhun S, "A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes : continuous spikes and waves during sleep is definitely a target", Seizure, 20, pp.320~325 (2011)
70. Muramatsu K, "Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy", Brain Dev, 39, pp.231~235 (2017)
71. Custer KL, "Synaptic vesicle protein 2 enhances release probability at quiescent synapses", J Neurosci, 26, pp.1303~1313 (2006)
72. Lynch BA, "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam", Proc Natl Acad Sci U S A, 101, pp.9861~9866 (2004)
73. Meehan AL, "A new mechanism for antiepileptic drug action : vesicular entry may mediate the effects of levetiracetam", J Neurophysiol, 106, pp.1227~1239 (2011)
74. Fukuyama K, "Levetiracetam inhibits neurotransmitter release associated with CICR", Neurosci Lett, 518, pp.69~74 (2012)
75. Hanada T, "Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy", Epilepsia, 52, pp.1331~1340 (2011)
76. Auvin S, "Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome", Epilepsy Behav, 74, pp.59~63 (2017)
77. Steinhoff BJ, "First clinical experiences with perampanel-the Kork experience in 74 patients", Epilepsia, 55(Suppl 1), pp.16~18 (2014)
78. Yelshanskaya MV, "Structural bases of noncompetitive inhibition of AMPA-subtype ionotropic glutamate receptors by antiepileptic drugs", Neuron, 91, pp.1305~1315 (2016)
79. Bourgeois BF, "Felbamate", Semin Pediatr Neurol, 4, pp.3~8 (1997)
80. Kleckner NW, "Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate : insights into the mechanism of action", J Pharmacol Exp Ther, 289, pp.886~894 (1999)
81. Pisani A, "Electrophysiological actions of felbamate on rat striatal neurones", Br J Pharmacol, 116, pp.2053~2061 (1995)
82. Rho JM, "Mechanism of action of the anticonvulsant felbamate : opposing effects on N-methyl-D-aspartate and γ-aminobutyric acidA receptors", Ann Neurol, 35, pp.229~234 (1994)
83. Rogawski MA, "Mechanisms of action of antiseizure drugs and the ketogenic diet", Cold Spring Harb Perspect Med (2016)
84. Wirrell EC, "Optimizing the diagnosis and management of Dravet syndrome : recommendations from a north American consensus panel", Pediatr Neurol, 68, pp.18~34 (2017)
85. Chiron C, "Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group", Lancet 2, 356, pp.1638~1642 (2000)
86. Ng YT, "Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome", Neurology, 77, pp.1473~1481 (2011)
87. Benarroch EE, "GABAA receptor heterogeneity, function, and implications for epilepsy", Neurology, 68, pp.612~614 (2007)
88. Quilichini PP, "Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels", Epilepsia, 47, pp.704~716 (2006)
89. Poisson M, "A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study", Arzneimittelforschung, 34, pp.199~204 (1984)
90. Korff CM, "Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin", Eur J Paediatr Neurol, 16, pp.753~757 (2012)
91. Cazorla MR, "Early infantile epileptic encephalopathy with unusual favourable outcome", Brain Dev, 32, pp.673~676 (2010)
92. Ben-Menachem E, "Mechanism of action of vigabatrin : correcting misperceptions", Acta Neurol Scand Suppl, 192, pp.5~15 (2011)
93. Petroff OA, "Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy", J Neurochem, 67, pp.2399~2404 (1996)
94. Wu Y, "Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release", J Neurophysiol, 89, pp.2021~2034 (2003)
95. Davis R, "Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy", Drugs, 47, pp.332~372 (1994)
96. Vassella F, "Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome", Schweiz Med Wochenschr, 108, pp.713~716 (1978)
97. Schmidt D, "A risk-benefit assessment of therapies for Lennox-Gastaut syndrome", Drug Saf, 22, pp.467~477 (2000)

관련 논문AI추천